Squibb/Novo-Nordisk
Executive Summary
Recent agreement with Danish firm for Squibb to develop, manufacture and share worldwide co-marketing rights for central nervous system compounds ("The Pink Sheet" May 8, In Brief), does not cover Novo-Nordisk's non-benzodiazepine anxiolytic FG-10571, its partial benzodiazepine receptor agonist FG-8119 or femoxitine, a 5HT-reuptake inhibitor with antidepressant properties. Novo-Nordisk has separate licensing arrangements for these three drugs.